A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer

BMC Cancer

Xue Qin Yu¹  Roberta De Angelis²  Qingwei Luo³  Clare Kahn³  Nehmat Houssami¹  Dianne L O’Connell⁴ 

[1] Sydney School of Public Health, University of Sydney, Sydney, Australia

[2] Centro Nazionale di Epidemiologia Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanità, Rome, Italy

[3] Cancer Research Division, Cancer Council New South Wales, Sydney, Australia

[4] School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

关键词: Australia;    Epidemiology;    Statistical projection;    Incidence;    Cancer prevalence;    Cancer survivorship;    Breast cancer;   

Others  :  1117908
DOI  :  10.1186/1471-2407-14-936

 received in 2014-09-08, accepted in 2014-12-06,  发布年份 2014

【 摘 要 】

Background

Breast cancer places a heavy burden on the Australian healthcare system, but information about the actual number of women living with breast cancer and their current or future health service needs is limited. We used existing population-based data and innovative statistical methods to address this critical research question in a well-defined geographic region.

Methods

Breast cancer data from the New South Wales (NSW) Central Cancer Registry and PIAMOD (Prevalence and Incidence Analysis MODel) software were used to project future breast cancer prevalence in NSW. Parametric models were fitted to incidence and survival data, and the modelled incidence and survival estimates were then used to estimate current and future prevalence. To estimate future healthcare requirements the projected prevalence was then divided into phases of care according to the different stages of the survivorship trajectory.

Results

The number of women in NSW living with a breast cancer diagnosis had increased from 19,305 in 1990 to 48,754 in 2007. This number is projected to increase further to 68,620 by 2017. The majority of these breast cancer survivors will require continued monitoring (31,974) or will be long-term survivors (29,785). About 9% will require active treatment (either initial therapy, or treatment for subsequent metastases or second cancer) and 1% will need end of life care due to breast cancer.

Conclusions

Extrapolating these projections to the national Australian population would equate to 209,200 women living with breast cancer in Australia in 2017, many of whom will require active treatment or post-treatment monitoring. Thus, careful planning and development of a healthcare system able to respond to this increased demand is required.

【 授权许可】

   
2014 Yu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Maddams J, Utley M, Moller H: Projections of cancer prevalence in the United Kingdom, 2010–2040. Br J Cancer 2012, 107(7):1195-1202.
• [3]Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML: Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011, 103(2):117-128.
• [4]Australian Institute of Health and Welfare & Cancer Australia: Breast Cancer in Australia: An Overview. Australia AIoHaWC: AIHW; 2012.
• [5]Australian Institute of Health and Welfare: Cancer incidence projections: Australia, 2011 to 2020. Canberra; [In. vol. Cancer Series no. 66. Cat. No. CAN 62]
• [6]Yu XQ, O’Connell DL, Gibberd RW, Coates AS, Armstrong BK: Trends in survival and excess risk of death after diagnosis of cancer in 1980–1996 in New South Wales, Australia. Int J Cancer 2006, 119(4):894-900.
• [7]Australian Institute of Health and Welfare: Cancer survival and prevalence in Australia: period estimates from 1982 to 2010. Asia Pac J Clin Oncol 2013, 9(1):29-39.
• [8]Brameld KJ, Holman CD, Threlfall TJ, Lawrence DM, De Kierk NH: Increasing ‘active prevalence’ of cancer in Western Australia and its implications for health services. Aust N Z J Public Health 2002, 26(2):164-169.
• [9]Brennan ME, Houssami N: Overview of long term care of breast cancer survivors. Maturitas 2011, 69(2):106-112.
• [10]McCabe MS, Faithfull S, Makin W, Wengstrom Y: Survivorship programs and care planning. Cancer 2013, 119(Suppl 11):2179-2186.
• [11]Verdecchia A, De Angelis G, Capocaccia R: Estimation and projections of cancer prevalence from cancer registry data. Stat Med 2002, 21(22):3511-3526.
• [12]Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH: Cancer survivors: a booming population. Cancer Epidemiol Biomarkers Prev 2011, 20(10):1996-2005.
• [13]Simonetti A, Gigli A, Capocaccia R, Mariotto A: Estimating complete prevalence of cancers diagnosed in childhood. Stat Med 2008, 27(7):990-1007.
• [14]Verdecchia A, De Angelis R, Francisci S, Grande E: Methodology for estimation of cancer incidence, survival and prevalence in Italian regions. Tumori 2007, 93(4):337-344.
• [15]Yu XQ, Clements M, O’Connell D: Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs. J Cancer Surviv 2013, 7(4):641-651.
• [16]Yu XQ, Smith DP, Clements MS, Patel MI, McHugh B, O’Connell DL: Projecting prevalence by stage of care for prostate cancer and estimating future health service needs: protocol for a modelling study. BMJ Open 2011, 1(1):e000104.
• [17]Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, Whelan S (Eds): International Classification of Diseases for Oncology. 3rd edition. Geneva, Switzerland: World Health Organisation; 2000.
• [18]Perme MP, Stare J, Esteve J: On estimation in relative survival. Biometrics 2012, 68(1):113-120.
• [19]Verdecchia A, De Angelis R, Capocaccia R, Sant M, Micheli A, Gatta G, Berrino F: The cure for colon cancer: results from the EUROCARE study. Int J Cancer 1998, 77(3):322-329.
• [20]Khan NF, Carpenter L, Watson E, Rose PW: Cancer screening and preventative care among long-term cancer survivors in the United Kingdom. Br J Cancer 2010, 102(7):1085-1090.
• [21]Smith SL, Singh-Carlson S, Downie L, Payeur N, Wai ES: Survivors of breast cancer: patient perspectives on survivorship care planning. J Cancer Surviv 2011, 5(4):337-344.
• [22]Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107(3):309-330.
• [23]Hsu T, Ennis M, Hood N, Graham M, Goodwin PJ: Quality of life in long-term breast cancer survivors. J Clin Oncol 2013, 31(28):3540-3548.
• [24]Canfell K, Banks E, Clements M, Kang YJ, Moa A, Armstrong B, Beral V: Sustained lower rates of HRT prescribing and breast cancer incidence in Australia since 2003. Breast Cancer Res Treat 2009, 117(3):671-673.
• [25]Canfell K, Banks E, Moa AM, Beral V: Decrease in breast cancer incidence following a rapid fall in use of hormone replacement therapy in Australia. Med J Aust 2008, 188(11):641-644.
• [26]Zbuk K, Anand SS: Declining incidence of breast cancer after decreased use of hormone-replacement therapy: magnitude and time lags in different countries. J Epidemiol Community Health 2012, 66(1):1-7.
• [27]Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s health initiative randomized controlled trial. JAMA 2002, 288(3):321-333.
• [28]Taylor R, Boyages J: Estimating risk of breast cancer from population incidence affected by widespread mammographic screening. J Med Screen 2001, 8(2):73-76.
• [29]Taylor R, Davis P, Boyages J: Long-term survival of women with breast cancer in New South Wales. Eur J Cancer 2003, 39(2):215-222.
• [30]Currow D, Thomson W: Cancer in NSW: Incidence Report 2009. Sydney: Cancer Institute NSW; 2014.
• [31]Anderson WF, Katki HA, Rosenberg PS: Incidence of breast cancer in the United States: current and future trends. J Natl Cancer Inst 2011, 103(18):1397-1402.
• [32]Australian Institute of Health and Welfare: Australian Institute of Health and Welfare. Older Australia at a glance 4th edition. 4th edition. Canberra: AIHW and DOHA; 2007.
• [33]Clements MS, Roder D, Yu XQ, Egger S, O’Connell DL: Estimating prevalence of distant metastatic breast cancer: a means of filling a data gap. Cancer Causes Control 2012, 23:1625-1634.
• [34]Gatta G, Mallone S, van der Zwan JM, Trama A, Siesling S, Capocaccia R, Group EW: Cancer prevalence estimates in Europe at the beginning of 2000. Ann Oncol 2013, 24(6):1660-1666.
• [35]Yu X, Baade P, O’Connell DL: Conditional survival of cancer patients: an Australian perspective. BMC Cancer 2012, 12:460. BioMed Central Full Text
• [36]Yu XQ, De Angelis R, Andersson TM, Lambert PC, O’Connell DL, Dickman PW: Estimating the proportion cured of cancer: some practical advice for users. Cancer Epidemiol 2013, 37(6):836-842.
• [37]Maher EJ, Makin W: Life after cancer treatment – a spectrum of chronic survivorship conditions. Clin Oncol (R Coll Radiol) 2007, 19(10):743-745.
• [38]Levit L, Smith AP, Benz EJ, Ferrell B: Ensuring quality cancer care through the oncology workforce. J Oncol Pract 2010, 6(1):7-11.
• [39]Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA: Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009, 27(17):2758-2765.